Rocuronium

Nondepolarizing Neuromuscular Blocker — MUSCULO-SKELETAL SYSTEM

Key facts

Rocuronium is an ofp drug in the Nondepolarizing Neuromuscular Blocker class catalogued in DrugCentral. It was first approved by the FDA in 1994. DrugCentral lists 2 molecular targets, including CHRNA1|CHRNB1|CHRND and CHRNA1|CHRNG|CHRNB1|CHRND. Recorded indications include General anesthesia, Muscle relaxation, function and Skeletal Muscle Relaxation for Endotracheal Intubation.

• Approval status: ofp (first approved 1994 by the FDA).
• Drug class: Nondepolarizing Neuromuscular Blocker.
• Molecular targets: CHRNA1|CHRNB1|CHRND and CHRNA1|CHRNG|CHRNB1|CHRND (2 listed in DrugCentral).
• Indications: General anesthesia, Muscle relaxation, function and Skeletal Muscle Relaxation for Endotracheal Intubation.
• ATC code: M03AC09 (Other quaternary ammonium compounds).
• Molecular formula: C32H53N2O4; molecular weight 529.78 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

• General anesthesia
• Muscle relaxation, function
• Skeletal Muscle Relaxation for Endotracheal Intubation

Contraindications (11)

• Acidosis
• Alkalosis
• Disease of liver
• Disorder of electrolytes
• Eaton-Lambert syndrome
• Kidney disease
• Malignant hyperthermia
• Myasthenia gravis
• Pulmonary hypertension
• Respiratory acidosis
• Respiratory alkalosis

Mechanism & targets

• Established pharmacologic class: Nondepolarizing Neuromuscular Blocker

Molecular targets (2)

Target	Gene	Action	Activity
Acetylcholine receptor	CHRNA1|CHRNB1|CHRND	antagonist	IC50 7.77
Acetylcholine receptor; alpha1/beta1/delta/gamma	CHRNA1|CHRNG|CHRNB1|CHRND	unknown	IC50 7.09

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1994-03-17	FDA	—	ORGANON USA INC

ATC classification

ATC code	Therapeutic hierarchy
M03AC09	MUSCULO-SKELETAL SYSTEM › MUSCLE RELAXANTS › MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS › Other quaternary ammonium compounds

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Anaphylactic shock	3937.6
Anaphylactic reaction	3268.6
Hypotension	1298.7
Cardiac arrest	1027.8
Bronchospasm	1006.1
Neuromuscular block prolonged	887.1
Hyperthermia malignant	821.2
Recurrence of neuromuscular blockade	634.6
Bradycardia	529.2
Delayed recovery from anaesthesia	484.9
Circulatory collapse	455.2
Tachycardia	451.7

Chemical structure

• Molecular formula: C₃₂H₅₃N₂O₄
• Molecular weight: 529.78 g/mol
• CAS number: 119302-91-9
• InChIKey: YXRDKMPIGHSVRX-OOJCLDBCSA-N
• PubChem CID: 441290

CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Rocuronium used for?

DrugCentral lists the following indications for Rocuronium: General anesthesia, Muscle relaxation, function and Skeletal Muscle Relaxation for Endotracheal Intubation.

How does Rocuronium work?

Its molecular targets in DrugCentral include CHRNA1|CHRNB1|CHRND (antagonist) and CHRNA1|CHRNG|CHRNB1|CHRND.

When was Rocuronium first approved?

Rocuronium was first approved by the FDA in 1994.

What drug class does Rocuronium belong to?

Rocuronium is in the Nondepolarizing Neuromuscular Blocker class.

What is the chemical formula of Rocuronium?

Rocuronium has the molecular formula C32H53N2O4 and a molecular weight of 529.78 g/mol.

Sources

• DrugCentral drug card 2396 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1200648 — compound record and bioactivity
• PubChem CID 441290 — chemical identifiers
• DrugBank DB00728 — drug record
• FDA UNII WRE554RFEZ — substance identity
• DailyMed: FDA labels for Rocuronium — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.